Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 670957, 17 pages
http://dx.doi.org/10.1155/2012/670957
Review Article

Incomplete Immune Recovery in HIV Infection: Mechanisms, Relevance for Clinical Care, and Possible Solutions

Department of Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, 2100 Copenhagen, Denmark

Received 24 November 2011; Accepted 22 December 2011

Academic Editor: Carlo Torti

Copyright © 2012 Julie C. Gaardbo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. G. Pakker, D. W. Notermans, R. J. De Boer et al., “Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation,” Nature Medicine, vol. 4, no. 2, pp. 208–214, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Autran, G. Carcelaint, T. S. Li et al., “Restoration of the immune system with anti-retroviral therapy,” Immunology Letters, vol. 66, no. 1-3, pp. 207–211, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Mocroft, A. Phillips, J. Gatell et al., “Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study,” Lancet, vol. 370, no. 9585, pp. 407–413, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. C. Piketty, P. Castiel, L. Belec et al., “Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease,” AIDS, vol. 12, no. 7, pp. 745–750, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Autran, G. Carcelain, T. S. Li et al., “Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease,” Science, vol. 277, no. 5322, pp. 112–116, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Marziali, W. De Santis, R. Carello et al., “T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART,” AIDS, vol. 20, no. 16, pp. 2033–2041, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. C. Erikstrup, G. Kronborg, N. Lohse, O. S. Rye, J. Gerstoft, and H. Ullum, “T-cell dysfunction in HIV-1-infected patients with impaired recovery of CD4 cells despite suppression of viral replication,” Journal of Acquired Immune Deficiency Syndromes, vol. 53, no. 3, pp. 303–310, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. Marchetti, L. Gazzola, D. Trabattoni et al., “Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART,” AIDS, vol. 24, no. 10, pp. 1455–1460, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. T. Li, N. Wu, Y. Dai et al., “Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy,” Clinical Infectious Diseases, vol. 53, no. 9, pp. 944–951, 2011. View at Publisher · View at Google Scholar · View at PubMed
  10. C. Lewden, G. Chêne, P. Morlat et al., “HIV-infected adults with a CD4 cell count greater than 500 cells/mm 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 1, pp. 72–77, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. “Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies,” Lancet, vol. 372, no. 9635, pp. 293–299, 2008.
  12. C. Piketty, L. Weiss, F. Thomas, A. S. Mohamed, L. Belec, and M. D. Kazatchkine, “Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen,” Journal of Infectious Diseases, vol. 183, no. 9, pp. 1328–1335, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. F. N. Engsig, J. Gerstoft, G. Kronborg et al., “Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study,” BMC Infectious Diseases, p. 318, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. D. Moore and J. C. Keruly, “CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression,” Clinical Infectious Diseases, vol. 44, no. 3, pp. 441–446, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. D'Amico, Y. Yang, D. Mildvan et al., “Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067,” Journal of Clinical Immunology, vol. 25, no. 2, pp. 106–115, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. R. Kaufmann, H. Furrer, B. Ledergerber et al., “Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy,” Clinical Infectious Diseases, vol. 41, no. 3, pp. 361–372, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. Greub, B. Ledergerber, M. Battegay et al., “Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the swiss HIV cohort study,” Lancet, vol. 356, no. 9244, pp. 1800–1805, 2000. View at Google Scholar · View at Scopus
  18. L. Kolte, C. Strandberg, A. M. Dreves et al., “Thymic involvement in immune recovery during antiretroviral treatment of HIV infection in adults; comparison of CT and sonographic findings,” Scandinavian Journal of Infectious Diseases, vol. 34, no. 9, pp. 668–672, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Kolte, A. M. Dreves, A. K. Ersbøll et al., “Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 185, no. 11, pp. 1578–1585, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. Vigano, S. Vella, N. Principi et al., “Thymus volume correlates with the progression of vertical HIV infection,” AIDS, vol. 13, no. 5, pp. F29–F34, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. D. C. Douek, R. A. Vescio, M. R. Betts et al., “Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution,” Lancet, vol. 355, no. 9218, pp. 1875–1881, 2000. View at Google Scholar · View at Scopus
  22. B. F. Haynes, M. L. Markert, G. D. Sempowski, D. D. Patel, and L. P. Hale, “The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection,” Annual Review of Immunology, vol. 18, pp. 529–560, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. M. McCune, R. Loftus, D. K. Schmidt et al., “High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection,” Journal of Clinical Investigation, vol. 101, no. 11, pp. 2301–2308, 1998. View at Google Scholar · View at Scopus
  24. K. Y. Smith, H. Valdez, A. Landay et al., “Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy,” Journal of Infectious Diseases, vol. 181, no. 1, pp. 141–147, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. B. D. Jamieson, D. C. Douek, S. Killian et al., “Generation of functional thymocytes in the human adult,” Immunity, vol. 10, no. 5, pp. 569–575, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Khoury, R. Rajasuriar, P. U. Cameron, and S. R. Lewin, “The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player,” Clinical Immunology, vol. 141, no. 3, pp. 253–267, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. S. Kimmig, G. K. Przybylski, C. A. Schmidt et al., “Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood,” Journal of Experimental Medicine, vol. 195, no. 6, pp. 789–794, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Junge, B. Kloeckener-Gruissem, R. Zufferey et al., “Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children,” European Journal of Immunology, vol. 37, no. 11, pp. 3270–3280, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. D. Hazenberg, S. A. Otto, J. W. T. C. Stuart et al., “Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection,” Nature Medicine, vol. 6, no. 9, pp. 1036–1042, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. D. C. Douek, R. D. McFarland, P. H. Keiser et al., “Changes in thymic function with age and during the treatment of HIV infection,” Nature, vol. 396, no. 6712, pp. 690–695, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. L. Zhang, S. R. Lewin, M. Markowitz et al., “Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy,” Journal of Experimental Medicine, vol. 190, no. 5, pp. 725–732, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Vrisekoop, R. Van Gent, A. B. De Boer et al., “Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging,” Journal of Immunology, vol. 181, no. 2, pp. 1573–1581, 2008. View at Google Scholar · View at Scopus
  33. S. Tanaskovic, S. Fernandez, M. A. French et al., “Thymic tissue is not evident on high-resolution computed tomography and [18F]Fluoro-deoxy-glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4+ T cells,” AIDS, vol. 25, no. 9, pp. 1235–1237, 2011. View at Publisher · View at Google Scholar · View at PubMed
  34. A. Isgrò, W. Leti, W. De Santis et al., “Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART,” Clinical Infectious Diseases, vol. 46, no. 12, pp. 1902–1910, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. P. Delobel, M. T. Nugeyre, M. Cazabat et al., “Naïve T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy,” Journal of Virology, vol. 80, no. 20, pp. 10229–10236, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. G. Marchetti, A. Gori, A. Casabianca et al., “Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART,” AIDS, vol. 20, no. 13, pp. 1727–1736, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. L. Kolte, L. P. Ryder, E. Albrecht-Beste, F. K. Jensen, and S. D. Nielsen, “HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy,” Scandinavian Journal of Immunology, vol. 70, no. 6, pp. 608–613, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Molina-Pinelo, J. Vivancos, B. De Felipe et al., “Thymic volume predicts CD4 T-cell decline in HIV-infected adults under prolonged treatment interruption,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 2, pp. 203–206, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. F. García, M. Plana, G. Mestre et al., “Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection,” AIDS, vol. 16, no. 13, pp. 1761–1765, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Van Gent, A. W.L. Schadenberg, S. A. Otto et al., “Long-term restoration of the human T-cell compartment after thymectomy during infancy: a role for thymic regeneration?” Blood, vol. 118, no. 3, pp. 627–634, 2011. View at Publisher · View at Google Scholar · View at PubMed
  41. G. Hütter and S. Ganepola, “Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells,” The Scientific World Journal, vol. 11, pp. 1068–1076, 2011. View at Publisher · View at Google Scholar · View at PubMed
  42. A. Marandin, A. Katz, E. Oksenhendler et al., “Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection,” Blood, vol. 88, no. 12, pp. 4568–4578, 1996. View at Google Scholar · View at Scopus
  43. A. Moses, J. Nelson, and G. C. Bagby, “The influence of human immunodeficiency virus-1 on hematopoiesis,” Blood, vol. 91, no. 5, pp. 1479–1495, 1998. View at Google Scholar · View at Scopus
  44. M. Jenkins, M. B. Hanley, M. B. Moreno, E. Wieder, and J. M. McCune, “Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo,” Blood, vol. 91, no. 8, pp. 2672–2678, 1998. View at Google Scholar · View at Scopus
  45. A. Alexaki and B. Wigdahl, “HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination,” PLoS Pathogens, vol. 4, no. 12, Article ID e1000215, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. C. C. Carter, A. Onafuwa-Nuga, L. A. McNamara et al., “HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs,” Nature Medicine, vol. 16, no. 4, pp. 446–451, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. Moir, J. Ho, A. Malaspina et al., “Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals,” Journal of Experimental Medicine, vol. 205, no. 8, pp. 1797–1805, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. W. Goodman and G. S. Hodgson, “Evidence for stem cells in the peripheral blood of mice,” Blood, vol. 19, pp. 702–714, 1962. View at Google Scholar · View at Scopus
  49. D. Sauce, M. Larsen, S. Fastenackels et al., “HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis,” Blood, vol. 117, no. 19, pp. 5142–5151, 2011. View at Publisher · View at Google Scholar · View at PubMed
  50. S. D. Nielsen, P. Afzelius, S. Dam-Larsen et al., “Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy,” Journal of Infectious Diseases, vol. 177, no. 6, pp. 1733–1736, 1998. View at Google Scholar · View at Scopus
  51. D. R. Clark, N. M. Ampel, C. A. Hallett, V. R. K. Yedavalli, N. Ahmad, and D. DeLuca, “Peripheral blood from human immunodeficiency virus type 1-infected patients displays diminished T cell generation capacity,” Journal of Infectious Diseases, vol. 176, no. 3, pp. 649–654, 1997. View at Google Scholar · View at Scopus
  52. L. S. Park, D. J. Friend, A. E. Schmierer, S. K. Dower, and A. E. Namen, “Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line,” Journal of Experimental Medicine, vol. 171, no. 4, pp. 1073–1089, 1990. View at Google Scholar · View at Scopus
  53. K. S. Schluns, W. C. Kieper, S. C. Jameson, and L. Lefrançois, “Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo,” Nature Immunology, vol. 1, no. 5, pp. 426–432, 2000. View at Google Scholar
  54. A. Llano, J. Barretina, A. Gutiérrez et al., “Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals,” Journal of Virology, vol. 75, no. 21, pp. 10319–10325, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. B. Rethi, C. Fluur, A. Atlas et al., “Loss of IL-7Rα is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients,” AIDS, vol. 19, no. 18, pp. 2077–2086, 2005. View at Google Scholar · View at Scopus
  56. G. M. Bellistri, A. Casabianca, E. Merlini et al., “Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy,” PLoS ONE, vol. 5, no. 12, article e15663, 2010. View at Publisher · View at Google Scholar · View at PubMed
  57. A. Leone, L. J. Picker, and D. L. Sodora, “IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment,” Current HIV Research, vol. 7, no. 1, pp. 83–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Ahmad, R. Ahmad, A. Iannello, E. Toma, R. Morisset, and S. T. A. K. Sindhu, “IL-15 and HIV infection: lessons for immunotherapy and vaccination,” Current HIV Research, vol. 3, no. 3, pp. 261–270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Sirskyj, J. Thèze, A. Kumar, and M. Kryworuchko, “Disruption of the γc cytokine network in T cells during HIV infection,” Cytokine, vol. 43, no. 1, pp. 1–14, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. D. Hazenberg, S. A. Otto, B. H. B. van Benthem et al., “Persistent immune activation in HIV-1 infection is associated with progression to AIDS,” AIDS, vol. 17, no. 13, pp. 1881–1888, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. Liu, W. G. Cumberland, L. E. Hultin, A. H. Kaplan, R. Detels, and J. V. Giorgi, “CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 18, no. 4, pp. 332–340, 1998. View at Google Scholar
  62. Z. Liu, W. G. Cumberland, L. E. Hultin, H. E. Prince, R. Detels, and J. V. Giorgi, “Elevated CD38 antigen expression on CD8+ T cells Is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS Cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 16, no. 2, pp. 83–92, 1997. View at Google Scholar
  63. Z. Liu, L. E. Hultin, W. G. Cumberland et al., “Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up,” Communications in Clinical Cytometry, vol. 26, no. 1, pp. 1–7, 1996. View at Publisher · View at Google Scholar · View at Scopus
  64. J. V. Giorgi, Z. Liu, L. E. Hultin, W. G. Cumberland, K. Hennessey, and R. Detels, “Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up,” Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 8, pp. 904–912, 1993. View at Google Scholar
  65. L. Weiss, N. Haeffner-Cavaillon, M. Laude, J. Gilquin, and M. D. Kazatchkine, “HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1α in vitro,” AIDS, vol. 3, no. 11, pp. 695–699, 1989. View at Google Scholar · View at Scopus
  66. J. M. Molina, D. T. Scadden, R. Byrn, C. A. Dinarello, and J. E. Groopman, “Production of tumor necrosis factor α and interleukin 1β by monocytic cells infected with human immunodeficiency virus,” Journal of Clinical Investigation, vol. 84, no. 3, pp. 733–737, 1989. View at Google Scholar · View at Scopus
  67. D. Emilie, M. Peuchmaur, M. C. Maillot et al., “Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes,” Journal of Clinical Investigation, vol. 86, no. 1, pp. 148–159, 1990. View at Google Scholar · View at Scopus
  68. D. L. Birx, R. R. Redfield, K. Tencer, A. Fowler, D. S. Burke, and G. Tosato, “Induction of interleukin-6 during human immunodeficiency virus infection,” Blood, vol. 76, no. 11, pp. 2303–2310, 1990. View at Google Scholar · View at Scopus
  69. J. V. Giorgi, L. E. Hultin, J. A. McKeating et al., “Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage,” Journal of Infectious Diseases, vol. 179, no. 4, pp. 859–870, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. A. E. Sousa, J. Carneiro, M. Meier-Schellersheim, Z. Grossman, and R. M. M. Victorino, “CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load,” Journal of Immunology, vol. 169, no. 6, pp. 3400–3406, 2002. View at Google Scholar · View at Scopus
  71. Z. Grossman, M. Meier-Schellersheim, A. E. Sousa, R. M. M. Victorino, and W. E. Paul, “CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?” Nature Medicine, vol. 8, no. 4, pp. 319–323, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. R. E. Owen, J. W. Heitman, D. F. Hirschkorn et al., “HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses,” AIDS, vol. 24, no. 8, pp. 1095–1105, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. S. R. Broussard, S. I. Staprans, R. White, E. M. Whitehead, M. B. Feinberg, and J. S. Allan, “Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease,” Journal of Virology, vol. 75, no. 5, pp. 2262–2275, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. A. Kaur, R. M. Grant, R. E. Means, H. Mcclure, M. Feinberg, and R. P. Johnson, “Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques,” Journal of Virology, vol. 72, no. 12, pp. 9597–9611, 1998. View at Google Scholar · View at Scopus
  75. E. L. Pesanti, “Effects of bacterial pneumonitis on development of pneumocystosis in rats,” American Review of Respiratory Disease, vol. 125, no. 6, pp. 723–726, 1982. View at Google Scholar · View at Scopus
  76. M. D. Hazenberg, D. Hamann, H. Schuitemaker, and F. Miedema, “T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock,” Nature Immunology, vol. 1, no. 4, pp. 285–289, 2000. View at Google Scholar · View at Scopus
  77. J. M. Benito, M. López, J. C. Martín et al., “Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors,” AIDS Research and Human Retroviruses, vol. 18, no. 18, pp. 1379–1388, 2002. View at Publisher · View at Google Scholar · View at PubMed
  78. P. W. Hunt, J. Brenchley, E. Sinclair et al., “Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy,” Journal of Infectious Diseases, vol. 197, no. 1, pp. 126–133, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. M. Massanella, E. Negredo, N. Pérez-Álvarez et al., “CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART,” AIDS, vol. 24, no. 7, pp. 959–968, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. D. Nakanjako, I. Ssewanyana, H. Mayanja-Kizza et al., “High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort,” BMC Infectious Diseases, vol. 11, article 43, 2011. View at Publisher · View at Google Scholar · View at PubMed
  81. J. M. Benito, M. López, S. Lozano et al., “CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation,” Journal of Infectious Diseases, vol. 192, no. 12, pp. 2142–2146, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. R. L. Gascon, A. B. Narváez, R. Zhang et al., “Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion,” Journal of Acquired Immune Deficiency Syndromes, vol. 30, no. 2, pp. 146–153, 2002. View at Google Scholar
  83. M. Mavigenr, P. Delobel, M. Cazabat et al., “HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy,” PLoS ONE, vol. 4, no. 10, Article ID e7658, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. P. Delobel, S. Flament, M. Hamdane et al., “Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis,” Journal of Neurochemistry, vol. 83, no. 2, pp. 412–420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Hazra and C. Mackall, “Thymic function in HIV infection,” Current HIV/AIDS Reports, vol. 2, no. 1, pp. 24–28, 2005. View at Google Scholar · View at Scopus
  86. R. B. Effros and G. Pawelec, “Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?” Immunology Today, vol. 18, no. 9, pp. 450–454, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. K. C. Wolthers, G. B. A. Wisman, S. A. Otto et al., “T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover,” Science, vol. 274, no. 5292, pp. 1543–1547, 1996. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Dagarag, H. Ng, R. Lubong, R. B. Effros, and O. O. Yang, “Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes,” Journal of Virology, vol. 77, no. 5, pp. 3077–3083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. O. Franzese, R. Adamo, M. Pollicita et al., “Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4+ T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1),” Journal of Medical Virology, vol. 79, no. 5, pp. 639–646, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. L. Meyaard, S. A. Otto, R. R. Jonker, M. J. Mijnster, R. P. M. Keet, and F. Miedema, “Programmed death of T cells in HIV-1 infection,” Science, vol. 257, no. 5067, pp. 217–219, 1992. View at Google Scholar · View at Scopus
  91. L. Meyaard, S. A. Otto, I. P. M. Keet, M. T. L. Roos, and F. Miedema, “Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease,” Journal of Clinical Investigation, vol. 93, no. 3, pp. 982–988, 1994. View at Google Scholar · View at Scopus
  92. F. Bottarel, S. Bonissoni, M. B. Lucia et al., “Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency,” Hematology Journal, vol. 2, no. 4, pp. 220–227, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. M. L. Gougeon, H. Lecoeur, A. Dulioust et al., “Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression,” Journal of Immunology, vol. 156, no. 9, pp. 3509–3520, 1996. View at Google Scholar · View at Scopus
  94. S. Piconi, D. Trabattoni, A. Gori et al., “Immune activation, apoptosis, and treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy,” AIDS, vol. 24, no. 13, pp. 1991–2000, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, “PD-1 and its ligands in tolerance and immunity,” Annual Review of Immunology, vol. 26, pp. 677–704, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. D. L. Barber, E. J. Wherry, D. Masopust et al., “Restoring function in exhausted CD8 T cells during chronic viral infection,” Nature, vol. 439, no. 7077, pp. 682–687, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. K. Grabmeier-Pfistershammer, P. Steinberger, A. Rieger, J. Leitner, and N. Kohrgruber, “Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 2, pp. 118–124, 2011. View at Publisher · View at Google Scholar · View at PubMed
  98. V. Appay, S. Fastenackels, C. Katlama et al., “Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients,” AIDS, vol. 25, no. 15, pp. 1813–1822, 2011. View at Publisher · View at Google Scholar · View at PubMed
  99. C. Steininger, E. Puchhammer-Stöckl, and T. Popow-Kraupp, “Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART),” Journal of Clinical Virology, vol. 37, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. S. Read, S. Mauze, C. Asseman, A. Bean, R. Coffman, and F. Powrie, “CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro,” European Journal of Immunology, vol. 28, no. 11, pp. 3435–3447, 1998. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Baecher-Allan, J. A. Brown, G. J. Freeman, and D. A. Hafler, “CD4+ CD25high regulatory cells in human peripheral blood,” Journal of Immunology, vol. 167, no. 3, pp. 1245–1253, 2001. View at Google Scholar · View at Scopus
  102. A. Yoshizawa, A. Ito, Y. Li et al., “The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation,” Transplantation Proceedings, vol. 37, no. 1, pp. 37–39, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. S. Sakaguchi, “Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self,” Nature Immunology, vol. 6, no. 4, pp. 345–352, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. K. Oswald-Richter, S. M. Grill, N. Shariat et al., “HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells,” PLoS Biology, vol. 2, no. 7, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. S. Tsunemi, T. Iwasaki, T. Imado et al., “Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients,” AIDS, vol. 19, no. 9, pp. 879–886, 2005. View at Google Scholar · View at Scopus
  106. J. C. Gaardbo, S. D. Nielsen, S. J. Vedel et al., “Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy,” Clinical and Experimental Immunology, vol. 154, no. 1, pp. 80–86, 2008. View at Publisher · View at Google Scholar · View at PubMed
  107. L. Kolte, J. C. Gaardbo, K. Skogstrand, L. P. Ryder, A. K. Ersbøll, and S. D. Nielsen, “Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs,” Clinical and Experimental Immunology, vol. 155, no. 1, pp. 44–52, 2009. View at Publisher · View at Google Scholar · View at PubMed
  108. A. Lim, D. Tan, P. Price et al., “Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy,” AIDS, vol. 21, no. 12, pp. 1525–1534, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. S. S. Bernardes, I. K. Borges, J. E. Lima et al., “Involvement of regulatory T cells in HIV immunopathogenesis,” Current HIV Research, vol. 8, no. 4, pp. 340–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. D. Favre, S. Lederer, B. Kanwar et al., “Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection,” PLoS Pathogens, vol. 5, no. 2, Article ID e1000295, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. D. Favre, J. Mold, P. W. Hunt et al., “Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease,” Science Translational Medicine, vol. 2, no. 32, pp. 32–36, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. P. W. Hunt, “Th17, gut, and HIV: therapeutic implications,” Current Opinion in HIV and AIDS, vol. 5, no. 2, pp. 189–193, 2010. View at Publisher · View at Google Scholar · View at PubMed
  114. L. Brandt, T. Benfield, H. Mens et al., “Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers,” Journal of Acquired Immune Deficiency Syndromes, vol. 57, no. 2, pp. 101–108, 2011. View at Publisher · View at Google Scholar · View at PubMed
  115. D. J. Hartigan-O'Connor, L. A. Hirao, J. M. McCune, and S. Dandekar, “Th17 cells and regulatory T cells in elite control over HIV and SIV,” Current Opinion in HIV and AIDS, vol. 6, no. 3, pp. 221–227, 2011. View at Publisher · View at Google Scholar · View at PubMed
  116. J. Gaardbo et al., “Regulatory T cells (Tregs) are extremely prevalent in HIV infected individuals with immunological non-response, oral presentation PS12/2,” European AIDS Clinical Society. In press.
  117. J. J. Mattapallil, D. C. Douek, B. Hill, Y. Nishimura, M. Martin, and M. Roederer, “Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection,” Nature, vol. 434, no. 7037, pp. 1093–1097, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. M. Guadalupe, E. Reay, S. Sankaran et al., “Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy,” Journal of Virology, vol. 77, no. 21, pp. 11708–11717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. T. W. Schacker, P. L. Nguyen, G. J. Beilman et al., “Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis,” Journal of Clinical Investigation, vol. 110, no. 8, pp. 1133–1139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. T. W. Schacker, C. Reilly, G. J. Beilman et al., “Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count,” AIDS, vol. 19, no. 18, pp. 2169–2171, 2005. View at Google Scholar · View at Scopus
  121. T. H. Finkel, G. Tudor-Williams, N. K. Banda et al., “Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes,” Nature Medicine, vol. 1, no. 2, pp. 129–134, 1995. View at Google Scholar · View at Scopus
  122. D. Finzi, M. Hermankova, T. Pierson et al., “Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy,” Science, vol. 278, no. 5341, pp. 1295–1300, 1997. View at Publisher · View at Google Scholar · View at Scopus
  123. W. Cavert, D. W. Notermans, K. Staskus et al., “Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection,” Science, vol. 276, no. 5314, pp. 960–964, 1997. View at Publisher · View at Google Scholar · View at Scopus
  124. T. W. Chun, D. C. Nickle, J. S. Justement et al., “Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy,” Journal of Infectious Diseases, vol. 197, no. 5, pp. 714–720, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. N. Chomont, M. El-Far, P. Ancuta et al., “HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation,” Nature Medicine, vol. 15, no. 8, pp. 893–900, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. L. Wang, C. W. Robb, and M. W. Cloyd, “HIV induces homing of resting T lymphocytes to lymph nodes,” Virology, vol. 228, no. 2, pp. 141–152, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. L. Wang, J. J. Y. Chen, B. B. Gelman, R. Konig, and M. W. Cloyd, “A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling through homing receptors,” Journal of Immunology, vol. 162, no. 1, pp. 268–276, 1999. View at Google Scholar · View at Scopus
  128. M. W. Cloyd, J. J. Y. Chen, P. Adeqboyega, and L. Wang, “How does HIV cause depletion of CD4 lymphocytes? A mechanism involving virus signaling through its cellular receptors,” Current Molecular Medicine, vol. 1, no. 5, pp. 545–550, 2001. View at Google Scholar · View at Scopus
  129. H. J. Epple, C. Loddenkemper, D. Kunkel et al., “Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART,” Blood, vol. 108, no. 9, pp. 3072–3078, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. K. Bhaskaran, O. Hamouda, M. Sannes et al., “Changes in the risk of death after HIV seroconversion compared with mortality in the general population,” JAMA - Journal of the American Medical Association, vol. 300, no. 1, pp. 51–59, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. F. Fedele, N. Bruno, and M. Mancone, “Cardiovascular risk factors and HIV disease,” AIDS Reviews, vol. 13, no. 2, pp. 119–129, 2011. View at Google Scholar
  132. S. K. Grinspoon, “Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus,” The American Journal of Medicine, vol. 118, supplement 2, pp. 23S–28S, 2005. View at Google Scholar · View at Scopus
  133. S. G. Deeks, “Antiretroviral treatment of HIV infected adults,” British Medical Journal, vol. 332, no. 7556, pp. 1489–1493, 2006. View at Google Scholar · View at Scopus
  134. N. R. Reynolds, “Cigarette smoking and HIV: more evidence for action,” AIDS Education and Prevention, vol. 21, no. 3, pp. 106–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. H. Van Tieu and B. A. Koblin, “HIV, alcohol, and noninjection drug use,” Current Opinion in HIV and AIDS, vol. 4, no. 4, pp. 314–318, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. A. A. Adimora and J. D. Auerbach, “Structural interventions for HIV prevention in the United States,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 2, supplement, pp. S132–S135, 2010. View at Publisher · View at Google Scholar · View at PubMed
  137. R. Greener and S. Sarkar, “Risk and vulnerability: do socioeconomic factors influence the risk of acquiring HIV in Asia?” AIDS, vol. 24, no. 3, supplement, pp. S3–S11, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  138. J. D. Lundgren, A. Babiker, W. El-Sadr et al., “Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up,” Journal of Infectious Diseases, vol. 197, no. 8, pp. 1145–1155, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  139. F. Gutiérrez, S. Padilla, M. Masiá et al., “Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy,” Current HIV Research, vol. 6, no. 2, pp. 100–107, 2008. View at Publisher · View at Google Scholar
  140. A. N. Phillips, B. Gazzard, R. Gilson et al., “Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count,” AIDS, vol. 21, no. 13, pp. 1717–1721, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. N. Obel, L. H. Omland, G. Kronborg et al., “Impact of Non-HIV and HIV risk factors on survival in HIV-Infected patients on haart: a population-based nationwide cohort study,” PLoS ONE, vol. 6, no. 7, article e22698, 2011. View at Publisher · View at Google Scholar · View at PubMed
  142. C. Smith, “Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study: the data collection on adverse events of anti-HIV drugs (D:A:D) study group,” AIDS, vol. 24, no. 10, pp. 1537–1548, 2010. View at Publisher · View at Google Scholar · View at PubMed
  143. L. Waters and C. A. Sabin, “Late HIV presentation: epidemiology, clinical implications and management,” Expert Review of Anti-Infective Therapy, vol. 9, no. 10, pp. 877–889, 2011. View at Publisher · View at Google Scholar · View at PubMed
  144. C. Mussini, “CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 × 106 cells/l,” AIDS, vol. 19, no. 3, pp. 287–294, 2005. View at Google Scholar
  145. J. D. Lundgren, “Combination antiretroviral therapy and the risk of myocardial infarction: the data collection on adverse events of anti-HIV drugs (DAD) Study Group,” New England Journal of Medicine, vol. 349, no. 21, pp. 1993–2003, 2003. View at Publisher · View at Google Scholar · View at PubMed
  146. J. V. Baker, W. K. Henry, and J. D. Neaton, “The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms,” Current Opinion in HIV and AIDS, vol. 4, no. 3, pp. 176–182, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  147. N. Friis-Møller, P. Reiss, C. A. Sabin et al., “Class of antiretroviral drugs and the risk of myocardial infarction,” New England Journal of Medicine, vol. 356, no. 17, pp. 1723–1735, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. A. N. Phillips, J. Neaton, and J. D. Lundgren, “The role of HIV in serious diseases other than AIDS,” AIDS, vol. 22, no. 18, pp. 2409–2418, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  149. R. C. Kaplan, L. A. Kingsley, S. J. Gange et al., “Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men,” AIDS, vol. 22, no. 13, pp. 1615–1624, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. H. W. Jaffe, B. L. De Stavola, L. M. Carpenter, K. Porter, and D. R. Cox, “Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults,” AIDS, vol. 25, no. 11, pp. 1395–1403, 2011. View at Publisher · View at Google Scholar · View at PubMed
  151. J. Bohlius, K. Schmidlin, D. Costagliola, G. Fatkenheuer, M. May, and A. M. Caro-Murillo, “Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study,” Antiviral Therapy, vol. 14, no. 8, pp. 1065–1074, 2009. View at Google Scholar
  152. E. Zanet, M. Berretta, F. Martellotta et al., “Anal cancer: focus on HIV-positive patients in the HAART era,” Current HIV Research, vol. 9, no. 2, pp. 70–81, 2011. View at Google Scholar
  153. A. D. Monforte, D. Abrams, C. Pradier et al., “HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies,” AIDS, vol. 22, no. 16, pp. 2143–2153, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  154. J. Reekie, C. Kosa, F. Engsig et al., “Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies,” Cancer, vol. 116, no. 22, pp. 5306–5315, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  155. R. K. Heaton, D. B. Clifford, D. R. Franklin et al., “HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: charter Study,” Neurology, vol. 75, no. 23, pp. 2087–2096, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  156. R. J. Ellis, J. Badiee, F. Vaida et al., “CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy,” AIDS, vol. 25, no. 14, pp. 1747–1751, 2011. View at Publisher · View at Google Scholar · View at PubMed
  157. J. A. Bartlett, M. J. Fath, R. DeMasi et al., “An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults,” AIDS, vol. 20, no. 16, pp. 2051–2064, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  158. R. M. Gulick, J. Lalezari, J. Goodrich et al., “Maraviroc for previously treated patients with R5 HIV-1 infection,” New England Journal of Medicine, vol. 359, no. 14, pp. 1429–1441, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  159. T. Wilkin et al., “Maraviroc intensification for suboptimal CD4+ cell response despite sustained virologic suppression: ACTG 5256,” in Proceedings of the 17th Conference on Retrovirus and Opportunistic Infections (CROI '10), abstract 285, 2010.
  160. T. J. Wilkin, H. R. Ribaudo, A. R. Tenorio, and R. M. Gulick, “The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients,” HIV Clinical Trials, vol. 11, no. 6, pp. 351–358, 2010. View at Publisher · View at Google Scholar · View at PubMed
  161. R. T. Steigbigel, D. A. Cooper, H. Teppler, J. J. Eron, J. M. Gatell, and P. N. Kumar, “Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials,” Clinical Infectious Diseases, vol. 50, no. 4, pp. 605–612, 2010. View at Google Scholar
  162. H. Hatano, T. L. Hayes, V. Dahl et al., “A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response,” Journal of Infectious Diseases, vol. 203, no. 7, pp. 960–968, 2011. View at Publisher · View at Google Scholar · View at PubMed
  163. H. Byakwaga, M. Kelly, D. F.J. Purcell et al., “Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial,” Journal of Infectious Diseases, vol. 204, no. 10, pp. 1532–1540, 2011. View at Publisher · View at Google Scholar · View at PubMed
  164. J.-M. Molina, A. LaMarca, J. Andrade-Villanueva et al., “Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study,” The Lancet Infectious Diseases, vol. 12, no. 1, pp. 27–35, 2012. View at Publisher · View at Google Scholar
  165. J. P. Lalezari, K. Henry, M. O'Hearn et al., “Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America,” New England Journal of Medicine, vol. 348, no. 22, pp. 2175–2185, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  166. A. Lazzarin, B. Clotet, D. Cooper et al., “Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia,” New England Journal of Medicine, vol. 348, no. 22, pp. 2186–2195, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  167. V. Joly et al., “Intensification of HAART through the addition of enfuvirtide in naive HIV-infected patients with severe immunosuppression does not improve immunological response: results of a prospective randomised multicenter trial,” in Proceedings of the 17th Conference on Retrovirus and Opportunistic Infections (CROI '10), abstract 282, 2010.
  168. S. L. Pett, A. D. Kelleher, and S. Emery, “Role of interleukin-2 in patients with HIV infection,” Drugs, vol. 70, no. 9, pp. 1115–1130, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  169. G. Carcelain, P. Saint-Mézard, H. K. Altes et al., “IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia,” AIDS, vol. 17, no. 6, pp. 841–850, 2003. View at Publisher · View at Google Scholar · View at Scopus
  170. F. Sabbatini, A. Bandera, G. Ferrario et al., “Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients,” PLoS ONE, vol. 5, no. 11, Article ID e14119, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  171. G. Marchetti, L. Meroni, S. Varchetta et al., “Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment,” Journal of Infectious Diseases, vol. 186, no. 5, pp. 606–616, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  172. C. L. MacKall, T. J. Fry, and R. E. Gress, “Harnessing the biology of IL-7 for therapeutic application,” Nature Reviews Immunology, vol. 11, no. 5, pp. 330–342, 2011. View at Publisher · View at Google Scholar · View at PubMed
  173. A. Leone, M. Rohankhedkar, A. Okoye et al., “Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses,” Journal of Immunology, vol. 185, no. 3, pp. 1650–1659, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  174. I. Sereti, R. M. Dunham, J. Spritzler et al., “IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection,” Blood, vol. 113, no. 25, pp. 6304–6314, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  175. Y. Levy, C. Lacabaratz, L. Weiss et al., “Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment,” Journal of Clinical Investigation, vol. 119, no. 4, pp. 997–1007, 2009. View at Publisher · View at Google Scholar · View at PubMed
  176. C. Sportès, F. T. Hakim, S. A. Memon et al., “Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets,” Journal of Experimental Medicine, vol. 205, no. 7, pp. 1701–1714, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  177. S. A. Rosenberg, C. Sportès, M. Ahmadzadeh et al., “IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells,” Journal of Immunotherapy, vol. 29, no. 3, pp. 313–319, 2006. View at Publisher · View at Google Scholar
  178. Y. Okamoto, D. C. Douek, R. D. McFarland, and R. A. Koup, “Effects of exogenous interleukin-7 on human thymus function,” Blood, vol. 99, no. 8, pp. 2851–2858, 2002. View at Publisher · View at Google Scholar · View at Scopus
  179. I. Sereti et al., “Recombinant IL-7 expands CD4 T cells in peripheral blood and gut mucosa of chronically HIV-infected immunological non-responder patients,” in Proceedings of the 18th Conference on Retrovirus and Opportunistic Infections (CROI '10), abstract 376, 2011.
  180. E. Lugli, Y. M. Mueller, M. G. Lewis, F. Villinger, P. D. Katsikis, and M. Roederer, “IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques,” Blood, vol. 118, no. 9, pp. 2520–2529, 2011. View at Publisher · View at Google Scholar · View at PubMed
  181. Y. M. Mueller, C. Petrovas, P. M. Bojczuk et al., “Interleukin-15 increases effector memory CD8+ T cells and NK cells in simian immunodeficiency virus-infected macaques,” Journal of Virology, vol. 79, no. 8, pp. 4877–4885, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  182. L. J. Picker, E. F. Reed-Inderbitzin, S. I. Hagen et al., “IL-15 induces CD4+ effector memory T cell production and tissue emigration in nonhuman primates,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1514–1524, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  183. Y. M. Mueller, D. H. Do, S. R. Altork et al., “IL-15 treatment during acute Simian Immunodeficiency Virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses,” Journal of Immunology, vol. 180, no. 1, pp. 350–360, 2008. View at Google Scholar · View at Scopus
  184. S. Benedini, I. Terruzzi, A. Lazzarin, and L. Luzi, “Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy,” BioDrugs, vol. 22, no. 2, pp. 101–112, 2008. View at Google Scholar · View at Scopus
  185. M. Gelato, M. McNurlan, and E. Freedland, “Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment,” Clinical Therapeutics, vol. 29, no. 11, pp. 2269–2288, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  186. K. Smith, L. Zheng, R. Bosch et al., “Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174,” AIDS Research and Human Retroviruses, vol. 26, no. 4, pp. 425–432, 2010. View at Google Scholar
  187. L. A. Napolitano, D. Schmidt, M. B. Gotway et al., “Growth hormone enhances thymic function in HIV-1-infected adults,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 1085–1098, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  188. L. A. Napolitano, J. C. Lo, M. B. Gotway et al., “Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone,” AIDS, vol. 16, no. 8, pp. 1103–1111, 2002. View at Publisher · View at Google Scholar · View at Scopus
  189. B. R. Hansen, L. Kolte, S. B. Haugaard et al., “Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study,” AIDS, vol. 23, no. 16, pp. 2123–2131, 2009. View at Google Scholar
  190. O. Andersen, B. R. Hansen, W. Troensegaard et al., “Sustained low-dose growth hormone therapy optimizes bioactive insulin-like growth factor-I level and may enhance CD4 T-cell number in HIV infection,” Journal of Medical Virology, vol. 82, no. 2, pp. 197–205, 2010. View at Publisher · View at Google Scholar · View at PubMed
  191. T. Sivakumar, O. J. Mechanic, D. A. Fehmie, and B. T. Paul, “Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials,” HIV Medicine, vol. 12, no. 8, pp. 453–462, 2011. View at Publisher · View at Google Scholar · View at PubMed
  192. S. Dhillon, “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy,” Drugs, vol. 71, no. 8, pp. 1071–1091, 2011. View at Publisher · View at Google Scholar · View at PubMed
  193. Y. Wang, G. Chen, S. Qiao et al., “Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant,” Leukemia and Lymphoma, vol. 52, no. 8, pp. 1556–1566, 2011. View at Publisher · View at Google Scholar · View at PubMed
  194. D. Min, A. Panoskaltsis-Mortari, M. Kuro-o, G. A. Holländer, B. R. Blazar, and K. I. Weinberg, “Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging,” Blood, vol. 109, no. 6, pp. 2529–2537, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  195. R. Seggewiss, K. Loré, F. J. Guenaga et al., “Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques,” Blood, vol. 110, no. 1, pp. 441–449, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  196. R. Rizwan, J. E. Levine, T. Defor et al., “Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation,” American Journal of Hematology, vol. 86, no. 10, pp. 879–882, 2011. View at Publisher · View at Google Scholar · View at PubMed
  197. B. R. Blazar, D. J. Weisdorf, T. DeFor et al., “Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT),” Blood, vol. 108, no. 9, pp. 3216–3222, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  198. D. Vassilopoulos and L. H. Calabrese, “Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections,” Current Opinion in Rheumatology, vol. 19, no. 6, pp. 619–625, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  199. S. F. Plaeger, B. S. Collins, R. Musib, S. G. Deeks, S. Read, and A. Embry, “Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary,” AIDS Research and Human Retroviruses, In press.
  200. J. N. Vermeulen, J. M. Prins, E. Bunnik et al., “Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals,” AIDS Research and Human Retroviruses, vol. 23, no. 11, pp. 1348–1353, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  201. A. Lindkvist, A. Edén, M. M. Norström et al., “Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study,” AIDS Research and Therapy, vol. 6, article 15, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  202. T. Mellberg, V. D. Gonzalez, A. Lindkvist et al., “Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV,” AIDS Research and Therapy, vol. 8, article 21, 2011. View at Publisher · View at Google Scholar · View at PubMed
  203. V. D. Gonzalez, K. Falconer, K. G. Blom et al., “High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment,” Journal of Virology, vol. 83, no. 21, pp. 11407–11411, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  204. P. W. Hunt, J. N. Martin, E. Sinclair et al., “Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD41+ T cell recovery on antiretroviral therapy,” Journal of Infectious Diseases, vol. 203, no. 10, pp. 1474–1483, 2011. View at Publisher · View at Google Scholar · View at PubMed
  205. P. W. Hunt, “Th17, gut, and HIV: therapeutic implications,” Current Opinion in HIV and AIDS, vol. 5, no. 2, pp. 189–193, 2010. View at Publisher · View at Google Scholar · View at PubMed
  206. E. Merlini, F. Bai, G. M. Bellistrì, C. Tincati, A. d'Arminio Monforte, and G. Marchetti, “Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy,” PLoS ONE, vol. 6, no. 4, article e18580, 2011. View at Publisher · View at Google Scholar · View at PubMed
  207. J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp. 1365–1371, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  208. W. Jiang, M. M. Lederman, P. Hunt et al., “Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection,” Journal of Infectious Diseases, vol. 199, no. 8, pp. 1177–1185, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  209. G. Marchetti, G. M. Bellistrì, E. Borghi et al., “Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy,” AIDS, vol. 22, no. 15, pp. 2035–2044, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  210. R. Hummelen, J. Changalucha, N. L. Butamanya et al., “Effect of 25 weeks probiotic supplementation on immune function of HIV patients,” Gut Microbes, vol. 2, no. 2, pp. 80–85, 2011. View at Google Scholar
  211. F. O. Pettersen, E. A. Torheim, A. E. Dahm et al., “An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses,” Journal of Virology, vol. 85, no. 13, pp. 6557–6566, 2011. View at Google Scholar
  212. D. Kvale, V. Ormaasen, A. M. B. Kran et al., “Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment,” AIDS, vol. 20, no. 6, pp. 813–820, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  213. C. C. Johansson, T. Bryn, E. M. Aandahl et al., “Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy,” AIDS, vol. 18, no. 6, pp. 951–952, 2004. View at Publisher · View at Google Scholar · View at Scopus